摘要
目的研究阿奇霉素联合布地奈德福莫特罗在支气管哮喘患者治疗中的作用。方法本研究中选取的样本,均为2017年4月至2019年4月前来我院治疗的支气管哮喘患者,总计108例,根据临床治疗方法进行分组,接受单一用药(布地奈德福莫特罗)的54例设为参照组,接受联合用药(阿奇霉素联合布地奈德福莫特罗)的54例则设为观察组,对比两组患者的治疗效果,并观察两组患者的肺功能改善情况。结果观察组治疗总有效率较参照组患者高,组间差异存在统计学意义(P<0.05);治疗后,可见两组患者的肺功能均有所改善,且观察组优于参照组(P<0.05);观察组患者出现不良反应的概率更低,仅有1例患者出现头晕症状,组间差异存在统计学意义(P<0.05)。结论阿奇霉素联合布地奈德福莫特罗治疗支气管哮喘患者能够有效改善肺功能,提升治疗效果,并未出现严重的不良反应。
Objective To study the effect of azithromycin combined with budesonide formoterol in the treatment of bronchial asthma.Methods This study included 108 samples,all of which were selected from bronchial asthma patients admitted to our hospital from April 2017 to April 2019.They were divided into groups according to the parity of patients'admission numbers.Among them,54 patients with even numbers were assigned to the observation group and 54 patients with odd numbers were assigned to the reference group.Only budesonide formoterol was given to the patients in the reference group,while azithromycin was added to the patients in the observation group on this basis to compare the therapeutic effects of the two groups of patients and observe the improvement of lung function of the two groups of patients.Results The total effective rate of treatment in the observation group was higher than that in the reference group,and the difference between the groups was statistically significant(P<0.05);after treatment,the lung function indexes of the two groups were improved compared with before treatment,and the observation group was better than the reference group(P<0.05);the total incidence of adverse reactions in the observation group was lower than that in the reference group,and the difference between the groups was statistically significant(P<0.05).Conclusion Azithromycin combined with budesonide formoterol can effectively improve lung function and treatment effect in bronchial asthma without serious adverse reactions,which is worthy of clinical promotion and application.
作者
卜范玉
BU Fanyu(Department of Respiratory Medicine,Fuxin Mine General Hospital,Liaoning Health Industry Group,Fuxin 123000,China)
出处
《中国医药指南》
2021年第24期47-48,共2页
Guide of China Medicine
